Testing new PSA subforms to enhance the accuracy of predicting cancer risk and disease outcome in prostate cancer.

Testing new PSA subforms to enhance the accuracy of predicting cancer risk and disease outcome in prostate cancer.

Bibliographic Details
Main Author:	Lilja, H
Format:	Journal article
Language:	English
Published:	2008

Similar Items

Can PSA velocity predict risk of death in men with prostate cancer?
by: Lilja, H, et al.
Published: (2007)

Prostate cancer: estimating the benefits of PSA screening.
by: Vickers, A, et al.
Published: (2009)

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
by: Ulmert, D, et al.
Published: (2008)

Role of hK2, free PSA, and complexed PSA measurements in the very early detection of prostate cancer.
by: Lilja, H
Published: (2001)

Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer.
by: Wiklund, F, et al.
Published: (2009)

Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
by: Denmeade, SR, et al.
Published: (2003)

Quantitative PSA RT-PCR for preoperative staging of prostate cancer.
by: Kurek, R, et al.
Published: (2003)

We need a better marker for prostate cancer. How about renaming PSA?
by: Vickers, A, et al.
Published: (2012)

PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section.
by: Khatami, A, et al.
Published: (2007)

A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer
by: Srinivasan, S, et al.
Published: (2024)

Contribution of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP) to the ongoing debate on the value of prostate cancer screening
by: Martin, RM, et al.
Published: (2022)

Erratum: PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section (International Journal of Cancer (2007) 120, (170-174))
by: Khatami, A, et al.
Published: (2007)

Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level.
by: Törnblom, M, et al.
Published: (2001)

Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.
by: Rosario, D, et al.
Published: (2008)

Measurements of proteases or protease system components in blood to enhance prediction of disease risk or outcome in possible cancer.
by: Lilja, H, et al.
Published: (2007)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
by: Lilja, H, et al.
Published: (2008)

Quality assessment for prostate-specific antigen (PSA) in relation to ERSPC: report of the PSA committee.
by: Blijenberg, BG, et al.
Published: (2003)

The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
by: Becker, C, et al.
Published: (2001)

PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK
by: Brett, J, et al.
Published: (2005)

Association between polymorphisms in the prostate-specific antigen (PSA) promoter and release of PSA.
by: Sävblom, C, et al.
Published: (2009)

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
by: O'Brien, M, et al.
Published: (2009)

Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age.
by: Sävblom, C, et al.
Published: (2005)

Alcohol consumption and PSA-detected prostate cancer risk--a case-control nested in the ProtecT study.
by: Zuccolo, L, et al.
Published: (2013)

Discrimination of prostate cancer from benign disease by selective measurements of serum subfractions of free PSA that are not internally cleaved at Lys145-Lys146
by: Nurmikko, P, et al.
Published: (2002)

Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
by: Oliver, SE, et al.
Published: (2004)

Screening for prostate cancer.
by: Carlsson, S, et al.
Published: (2012)

Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
by: Björk, T, et al.
Published: (2001)

Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring (Corrigendum) (Nature Reviews Cancer (2008) 8, (268-278))
by: Lilja, H, et al.
Published: (2008)

PSA is dead, long live PSA.
by: Vickers, A, et al.
Published: (2012)

Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study.
by: Burton, A, et al.
Published: (2013)

Survival and PSA relapse data after hypofiractionated radiotherapy for early stage prostate cancer
by: Law, A, et al.
Published: (2007)

A four‐group urine risk classifier for predicting outcomes in patients with prostate cancer
by: Connell, SP, et al.
Published: (2019)

Circulating biomarkers for prostate cancer.
by: Steuber, T, et al.
Published: (2007)

Screening for prostate cancer: an update.
by: Shariat, S, et al.
Published: (2008)

Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis.
by: Roddam, A, et al.
Published: (2005)

Prediction of tumor heterogeneity in localized prostate cancer.
by: Huland, H, et al.
Published: (2002)

Predicting prostate cancer many years before diagnosis: how and why?
by: Vickers, A, et al.
Published: (2012)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
by: Vickers, A, et al.
Published: (2010)

Measurement of the insulin-like growth factor (IGF)-axis does not enhance the specificity of PSA-based prostate cancer screening.
by: Oliver, SE, et al.
Published: (2002)

Urological cancer: Time for another rethink on prostate cancer screening.
by: Vickers, A, et al.
Published: (2012)